Inovio (INO) Receives Upgrade to Buy: Reasons Behind the Decision
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy INO?
Source: NASDAQ.COM
Inovio Pharmaceuticals Upgrade: Inovio Pharmaceuticals has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.
Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.
Earnings Estimates: Analysts have raised their earnings estimates for Inovio, with a 5% increase in the Zacks Consensus Estimate over the past three months, reflecting an improvement in the company's underlying business.
Market Positioning: The upgrade places Inovio in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price increases driven by positive earnings revisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.580
Low
3.00
Averages
7.33
High
13.00
Current: 1.580
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Filed Against Inovio Pharmaceuticals for Misleading Statements
- Class Action Initiation: The Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file their motions with the court by April 7, 2026, indicating their intent to represent other class members in the litigation, ensuring their rights are protected.
- Compensation Mechanism Explained: Investors participating in the class action may receive compensation without any upfront costs, as the law firm will operate on a contingency fee basis, alleviating the financial burden on investors.
- Regulatory Challenges for Inovio: The lawsuit claims that Inovio's manufacturing deficiencies for its CELLECTRA device diminish the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024, thereby impacting the company's market prospects and investor confidence.
See More
Faruqi & Faruqi Investigates Potential Claims Against Inovio Pharmaceuticals
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Inovio Pharmaceuticals, particularly for investors who purchased securities between October 10, 2023, and December 26, 2025, indicating significant legal risks that could impact stock prices and investor confidence.
- Allegations of False Statements: The lawsuit alleges that Inovio and its executives violated federal securities laws by failing to disclose manufacturing deficiencies in its CELLECTRA device, which diminishes the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024, thereby affecting the company's future market prospects.
- FDA Review Dynamics: Although Inovio announced on December 29, 2025, that its INO-3107 Biologics License Application was accepted by the FDA, the agency noted that the company did not provide adequate information to justify eligibility for accelerated approval, leading to a 24.45% drop in stock price, reflecting market concerns over regulatory prospects.
- Investor Rights Protection: Faruq & Faruqi LLP reminds investors that April 7, 2026, is the deadline to apply to become the lead plaintiff in the federal securities class action, emphasizing the importance of investor participation in legal proceedings and potential economic recovery opportunities.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegations: The complaint alleges that Inovio made false and misleading statements regarding manufacturing deficiencies of its CELLECTRA device and indicated that it was unlikely to file the INO-3107 BLA by the second half of 2024, resulting in investor losses when the truth emerged.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs; those who take no action will remain absent class members and may miss out on potential recovery.
- Investor Rights Protection: The Schall Law Firm specializes in securities class action lawsuits and encourages affected investors to reach out for free consultations to discuss their rights and seek recovery of their losses.
See More
Inovio Pharmaceuticals Faces Class Action for Investor Misleading
- Lawsuit Background: Robbins LLP reminds shareholders of a class action filed on behalf of all individuals who purchased Inovio Pharmaceuticals (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, alleging the company misled investors regarding the approval of its CELLECTRA device.
- Manufacturing Defect Disclosure: According to the complaint, Inovio admitted in its August 8, 2024, earnings report that due to manufacturing issues with the CELLECTRA device, it would delay the submission of the INO-3107 Biologics License Application (BLA) to the FDA until mid-2025, a full year later than initially projected, causing a 3.1% drop in stock price.
- Regulatory Outlook Deterioration: On December 29, 2025, Inovio announced that the FDA accepted the INO-3107 BLA on a standard review timeline rather than an accelerated one, indicating the company failed to provide adequate information to justify eligibility for accelerated approval, leading to a further 24.45% decline in stock price.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers to the court by April 7, 2026, with Robbins LLP offering contingency fee representation, ensuring shareholders incur no costs in the litigation.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Misleading Statements
- Lawsuit Background: The Law Offices of Howard G. Smith has filed a class action lawsuit on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, requiring lead plaintiff motions by April 7, 2026, indicating significant uncertainty about the company's future.
- Financial Impact: On August 8, 2024, Inovio reported its Q2 financial results, revealing a delay in submitting the INO-3107 BLA to mid-2025 due to manufacturing issues, causing a 3.1% drop in stock price to $8.44 per share the following day, directly affecting investor confidence.
- FDA Approval Delay: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 application but did not grant accelerated review, leading to a 24.45% stock price drop to $1.73 per share, further exacerbating investor losses.
- False Statement Allegations: The lawsuit alleges that throughout the class period, the company made materially false or misleading statements and failed to disclose manufacturing deficiencies and poor regulatory prospects, severely undermining investor confidence in the company's future.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their rights.
- BlackRock TCP Lawsuit Details: The lawsuit alleges that from November 2024 to January 2026, BlackRock failed to timely and appropriately value investments, leading to understated unrealized losses and inflated net asset value (NAV), resulting in significant losses for investors.
- Oracle Lawsuit Impact: Between June and December 2025, Oracle's AI infrastructure strategy resulted in massive capital expenditure increases without corresponding revenue growth, raising serious risks regarding the company's debt and credit rating, which could adversely affect investors' financial positions.
- Risks for Paysafe and Inovio: The lawsuit against Paysafe, covering March to November 2025, highlights its significant exposure to high-risk clients, potentially hindering revenue growth, while Inovio faces challenges in submitting its FDA application on time due to manufacturing deficiencies, both posing substantial risks to investors.
See More
Class Action Filed Against Inovio Pharmaceuticals for Misleading Statements
- Class Action Initiation: The Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file their motions with the court by April 7, 2026, indicating their intent to represent other class members in the litigation, ensuring their rights are protected.
- Compensation Mechanism Explained: Investors participating in the class action may receive compensation without any upfront costs, as the law firm will operate on a contingency fee basis, alleviating the financial burden on investors.
- Regulatory Challenges for Inovio: The lawsuit claims that Inovio's manufacturing deficiencies for its CELLECTRA device diminish the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024, thereby impacting the company's market prospects and investor confidence.
See More
Faruqi & Faruqi Investigates Potential Claims Against Inovio Pharmaceuticals
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Inovio Pharmaceuticals, particularly for investors who purchased securities between October 10, 2023, and December 26, 2025, indicating significant legal risks that could impact stock prices and investor confidence.
- Allegations of False Statements: The lawsuit alleges that Inovio and its executives violated federal securities laws by failing to disclose manufacturing deficiencies in its CELLECTRA device, which diminishes the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024, thereby affecting the company's future market prospects.
- FDA Review Dynamics: Although Inovio announced on December 29, 2025, that its INO-3107 Biologics License Application was accepted by the FDA, the agency noted that the company did not provide adequate information to justify eligibility for accelerated approval, leading to a 24.45% drop in stock price, reflecting market concerns over regulatory prospects.
- Investor Rights Protection: Faruq & Faruqi LLP reminds investors that April 7, 2026, is the deadline to apply to become the lead plaintiff in the federal securities class action, emphasizing the importance of investor participation in legal proceedings and potential economic recovery opportunities.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegations: The complaint alleges that Inovio made false and misleading statements regarding manufacturing deficiencies of its CELLECTRA device and indicated that it was unlikely to file the INO-3107 BLA by the second half of 2024, resulting in investor losses when the truth emerged.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs; those who take no action will remain absent class members and may miss out on potential recovery.
- Investor Rights Protection: The Schall Law Firm specializes in securities class action lawsuits and encourages affected investors to reach out for free consultations to discuss their rights and seek recovery of their losses.
See More
Inovio Pharmaceuticals Faces Class Action for Investor Misleading
- Lawsuit Background: Robbins LLP reminds shareholders of a class action filed on behalf of all individuals who purchased Inovio Pharmaceuticals (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, alleging the company misled investors regarding the approval of its CELLECTRA device.
- Manufacturing Defect Disclosure: According to the complaint, Inovio admitted in its August 8, 2024, earnings report that due to manufacturing issues with the CELLECTRA device, it would delay the submission of the INO-3107 Biologics License Application (BLA) to the FDA until mid-2025, a full year later than initially projected, causing a 3.1% drop in stock price.
- Regulatory Outlook Deterioration: On December 29, 2025, Inovio announced that the FDA accepted the INO-3107 BLA on a standard review timeline rather than an accelerated one, indicating the company failed to provide adequate information to justify eligibility for accelerated approval, leading to a further 24.45% decline in stock price.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers to the court by April 7, 2026, with Robbins LLP offering contingency fee representation, ensuring shareholders incur no costs in the litigation.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Misleading Statements
- Lawsuit Background: The Law Offices of Howard G. Smith has filed a class action lawsuit on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, requiring lead plaintiff motions by April 7, 2026, indicating significant uncertainty about the company's future.
- Financial Impact: On August 8, 2024, Inovio reported its Q2 financial results, revealing a delay in submitting the INO-3107 BLA to mid-2025 due to manufacturing issues, causing a 3.1% drop in stock price to $8.44 per share the following day, directly affecting investor confidence.
- FDA Approval Delay: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 application but did not grant accelerated review, leading to a 24.45% stock price drop to $1.73 per share, further exacerbating investor losses.
- False Statement Allegations: The lawsuit alleges that throughout the class period, the company made materially false or misleading statements and failed to disclose manufacturing deficiencies and poor regulatory prospects, severely undermining investor confidence in the company's future.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their rights.
- BlackRock TCP Lawsuit Details: The lawsuit alleges that from November 2024 to January 2026, BlackRock failed to timely and appropriately value investments, leading to understated unrealized losses and inflated net asset value (NAV), resulting in significant losses for investors.
- Oracle Lawsuit Impact: Between June and December 2025, Oracle's AI infrastructure strategy resulted in massive capital expenditure increases without corresponding revenue growth, raising serious risks regarding the company's debt and credit rating, which could adversely affect investors' financial positions.
- Risks for Paysafe and Inovio: The lawsuit against Paysafe, covering March to November 2025, highlights its significant exposure to high-risk clients, potentially hindering revenue growth, while Inovio faces challenges in submitting its FDA application on time due to manufacturing deficiencies, both posing substantial risks to investors.
See More
